Mektovi and Retinal disturbances
Result of checking the interaction of drug Mektovi and disease Retinal disturbances for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:Retinal vein occlusion (RVO) is a known class- related adverse reaction of MEK inhibitors and may occur in patients treated with binimetinib in combination with encorafenib. The safety of binimetinib has not been established in patients with a history of RVO or current risk factors for RVO including uncontrolled glaucoma or a history of hyperviscosity or hypercoagulability syndromes. An ophthalmologic evaluation should be performed for patient reporting acute vision loss or other visual disturbance within 24 hours. Treatment should be discontinued in patients with documented RVO.